Tislelizumab
- Generic Name
- Tislelizumab
- Brand Names
- Tevimbra, Tizveni
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1858168-59-8
- Unique Ingredient Identifier
- 0KVO411B3N
- Background
Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
- Indication
⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤（R/R cHL）患者。
⑵用于治疗局部晚期或转移性尿路上皮癌。
⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌（NSCLC）患者。
⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。
⑸用于治疗晚期恶性实体瘤
- Associated Conditions
- -
- Associated Therapies
- -
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 90
- Registration Number
- NCT05981703
- Locations
- 🇦🇺
Icon Cancer Centre Kurralta Park, Kurralta Park, South Australia, Australia
🇨🇳Jining No Peoples Hospital West Branch, Jining, Shandong, China
🇨🇳Taizhou Hospital of Zhejiang Province (East), Taizhou, Zhejiang, China
IN10018 Combination Therapy in Previously-treated Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- InxMed (Shanghai) Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT05982522
Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 28
- Registration Number
- NCT05977673
- Locations
- 🇮🇹
A.O. SS. Antonio e Biagio e Cesare Arrigo, S.C. Ematologia, Alessandria, IT, Italy
🇮🇹Divisione di Oncologia e dei Tumori immuto-correlati, Centro Di Riferimento Oncologico Di Aviano, Aviano, Italy
🇮🇹Istituto di Ematologia L. e A. Seràgnoli, AOU Policlinico S. Orsola-Malpighi, Bologna, Italy
RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression
- Conditions
- Interventions
- First Posted Date
- 2023-07-24
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05957757
- Locations
- 🇨🇳
Ethics Committee of Shanghai Renji Hospital, Shanghai, Shanghai, China
A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 318
- Registration Number
- NCT05935098
- Locations
- 🇦🇺
Linear Clinical Research, Nedlands, Western Australia, Australia
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸Next Dallas, Irving, Texas, United States
A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Renmin Hospital of Wuhan University
- Target Recruit Count
- 155
- Registration Number
- NCT05919030
- Locations
- 🇨🇳
Renmin hosptial of Wuhan University, Wuhan, Hubei, China
Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 160
- Registration Number
- NCT05909904
- Locations
- 🇹🇭
Siriraj Hospital, Bangkok, Thailand
🇹🇭Ramathibodi Hospital Mahidol University, Bangkok, Thailand
🇰🇷Keimyung University Dongsan Hospital, Dalseogu, Daegu Gwang'yeogsi, Korea, Republic of
KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Shanghai Kanda Biotechnology Co., Ltd.
- Target Recruit Count
- 85
- Registration Number
- NCT05906524
- Locations
- 🇨🇳
Zhongshan Hospital, Shanghai, China
A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 200
- Registration Number
- NCT05904496
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Md Anderson Cancer Center, Houston, Texas, United States
🇺🇸Next Oncology, San Antonio, Texas, United States
Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-13
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 132
- Registration Number
- NCT05900921
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.